Tarceva Coupons & Savings Card – Discount Prices from $99.00

Tarceva (erlotinib) has not been discontinued. It is still available and used in the treatment of certain types of cancer, such as non-small cell lung cancer and pancreatic cancer. However, there may be specific circumstances or regions where availability is affected due to regulatory decisions, market demand, or other factors. It is important for patients to consult with their healthcare provider for the most current information regarding their treatment options.

Tarceva is used for the treatment of certain types of non-small cell lung cancer (NSCLC) and pancreatic cancer. It is typically prescribed for patients whose cancer has spread to other parts of the body and is used when other treatments have not been effective.

The choice between Tagrisso (osimertinib) and Tarceva (erlotinib) depends on several factors, including the specific type of EGFR mutation present in the cancer, the stage of the disease, and the patient's overall health condition. Tagrisso is often preferred for patients with non-small cell lung cancer (NSCLC) that has a specific EGFR T790M mutation or as a first-line treatment for certain types of EGFR mutations. It is known for its efficacy in crossing the blood-brain barrier, which can be beneficial in cases with brain metastases. However, the decision should be made by the healthcare provider based on the individual patient's clinical scenario.

The most common side effect of erlotinib is a skin rash.

Erlotinib can cause several toxicities, including rash, diarrhea, fatigue, and anorexia. Other potential side effects include interstitial lung disease, hepatotoxicity, and gastrointestinal perforation. Patients may also experience nausea, vomiting, and ocular disorders. It is important for patients to be monitored regularly for these adverse effects during treatment.